Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069660 · ClinicalTrials.gov registry record · NA
Compass 3: A Novel Transition Program to Reduce Disability After Stroke
A NA study of Stroke, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 520
- Enrollment target
- 2
- Study locations
NCT07069660: Recruiting NA study of Stroke, sponsored by Washington University School of Medicine.
NCT07069660 is a NA study of Stroke that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 520 participants, below the 12,015-participant average among 454 other Stroke trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07069660, a NA study of Stroke, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 520 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates a program designed to help individuals transition from inpatient rehabilitation to home following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.
Primary Outcome
Date and days of admission to a skilled nursing facility
Conditions Studied
Interventions
- BEHAVIORAL COMPASS
- BEHAVIORAL Education Program
Study Locations (2)
Missouri
- University of Missouri - Columbia
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2030-03-31 |
| Phase | NA |
What NCT07069660 shows while recruiting
NCT07069660 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 12,015-participant average among 454 other Stroke trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which COMPASS is the first listed.
NCT07069660 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07069660 about?
NCT07069660 is a clinical study titled "Compass 3: A Novel Transition Program to Reduce Disability After Stroke". This study evaluates a program designed to help individuals transition from inpatient rehabilitation to home following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.
What is the current status of trial NCT07069660?
This trial is currently recruiting. It is a NA study. The enrollment target is 520 participants. The study started on 2025-09-29. Estimated completion is 2030-03-31.
What conditions does trial NCT07069660 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT07069660?
The interventions under investigation include: COMPASS (BEHAVIORAL), Education Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT07069660?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069660 being conducted?
This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07069660's enrollment target sits among peer trials
520 56th of 454 higher than 399 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI